Recent articles
Is Canopy Growth’s Stock About to Double?
Canopy Growth crushed estimates during the third quarter, and it could be just the beginning of a rebound.
Is Intercept Pharmaceuticals Stock a Buy?
Despite only having one product on the market, Intercept Pharmaceuticals is worth considering.
Is This the Turning Point for Uber?
After a forgettable first nine months as a publicly traded company, is Uber finally ready to live up to the lofty expectations?
Spotify's Podcast Strategy Continues to Pay Off
It looks like Spotify is making the right moves.
Is Aurora Cannabis Stock a Buy?
Aurora Cannabis has faced a slate of issues recently, but do they represent a buying opportunity?
So Far, Apple Is Losing the Streaming War
Apple TV+ isn't keeping up with the competition.
Is Merck & Co. Stock a Buy?
Keytruda will continue to be a growth driver for Merck, but the company is looking elsewhere for growth as well.
2 Reasons to Be Optimistic About Gilead Sciences’ Future
Despite poor performances in recent years, here's why Gilead Sciences could turn things around.
Even With FTC Challenge and Leadership Change, Match Is Still Worth Considering
Here's why investors might want to swipe right on Match.
This Cannabis Stock Started the Year on Fire: Should You Buy the Hype?
Can OrganiGram maintain its momentum?
With Solid Fourth Quarter Results, AbbVie Shows That Its Growth Days Are Far From Over
Despite Humira's declining international sales, AbbVie is still worth considering.
Is GW Pharmaceuticals Stock a Buy?
Should investors worry about Epidiolex's slowing sales growth?
Things Will Only Get Harder From Here On Out for Snap
An increasingly competitive landscape could derail Snap's comeback story.
How Apple Proved the Doubters Wrong With Its Latest Earnings Report
The iPhone maker isn't done growing just yet.
Bristol-Myers Squibb Stock Is Too Cheap to Ignore
The acquisition of Celgene is working wonders so far.
Aimmune Therapeutics Just Made History: Is It a Buy?
The food allergy specialist just landed its first approval.
3 Reasons to Be Optimistic About PayPal
Investors should overlook PayPal's weak guidance for 2020.
Facebook’s Post-Earnings Sell-Off Is an Opportunity for Investors
Facebook’s recent slump isn’t the end of the world.
In a Mixed Quarter, Johnson & Johnson Shows Off Its Greatest Strength
Despite slow revenue growth, the healthcare company has much to offer investors.
Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences
What does the future hold for these two biotech stocks?